Literature DB >> 342086

The clinical pharmacology of methotrexate: new applications of an old drug.

W A Bleyer.   

Abstract

Methotrexate is now used widely for the treatment of acute leukemia, non-Hodgkin's lymphoma, osteogenic sarcoma, choriocarcinoma, breast carcinoma, pulmonary and epidermoid carcinoma, and intrathecal chemotherapy. It is also useful in bone marrow transplantation, severe psoriasis, rheumatoid arthritis, dermatomyositis, Wegener's granulomatosis and sarcoidosis. The recent dramatic intensification of methotrexate therapy can be attributed in part to advances in our understanding of the clinical pharmacology of the folate antagonists, as well as to the combination of positive results and their effective dissemination to medical oncologists. The review summarizes the pharmacologic findings and illustrates how they are currently being applied to the treatment of malignant disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 342086     DOI: 10.1002/1097-0142(197801)41:1<36::aid-cncr2820410108>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  119 in total

1.  Are glomerular filtration rate estimations necessary before high dose methotrexate?

Authors:  H Rees; I M Hann; J M Chessells; D K Webb
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

Review 2.  New developments in sustained release drug delivery for the treatment of intraocular disease.

Authors:  G Velez; S M Whitcup
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 3.  Adverse effects of cancer chemotherapy. An overview of techniques for avoidance/minimisation.

Authors:  M Nicolson; R C Leonard
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

4.  Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer.

Authors:  Erin Dombrowsky; Bhuvana Jayaraman; Mahesh Narayan; Jeffrey S Barrett
Journal:  Ther Drug Monit       Date:  2011-02       Impact factor: 3.681

5.  Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats.

Authors:  S Kurth; D Bulian; B Kreft; T Riemenschneider
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.

Authors:  C Wolfrom; R Hepp; R Hartmann; H Breithaupt; G Henze
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Comparison of linear and tapered intravenous infusion of methotrexate in oncochemotherapy. A theoretical approach.

Authors:  E F Termond; B Zonnenberg; B Winograd; M J Oosterbaan; E Van der Kleijn; T B Vree
Journal:  Pharm Weekbl Sci       Date:  1985-08-23

8.  Methotrexate-induced oral mucositis and salivary methotrexate concentrations.

Authors:  A Oliff; W A Bleyer; D G Poplack
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  Combined ultrastructural, histochemical, and autoradiographic study of osteosarcoma after preoperative chemotherapy according to the COSS 80 protocol.

Authors:  E Grundmann; A Roessner; W Schlake; M Immenkamp; P Preusser; G Wüst; J Ritter; E Schnepper
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

10.  Topical methotrexate alters solute and water transport in the rat jejunum in vivo and rabbit ileum in vitro.

Authors:  C R Pinkerton; I W Booth; P J Milla
Journal:  Gut       Date:  1985-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.